This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Drug Enforcement Administration (DEA) got a slap on the wrist from a federal watchdog agency over its management of a multi-million dollar marijuana eradication program. And that lapse could prevent the agency from being able to accurately assess “program performance.”.
ASA has recently revamped our Member Benefits Program, adding new benefits for our members each month like the 20% off offer on Nectar Products (see article below on Nectar) & 50% off registration for the upcoming Validated Voices Summit in September. Is your membership Current?
Indeed, the DEA reports that it is “aggressively striving to halt the spread of cannabis cultivation in the United States,” including through its Domestic Cannabis Eradication/Suppression Program (DCE/SP), which began funding eradication programs in 1979 and has approximately 126 state and local law enforcement agency participants.
The annual DEA report also shows that federal law enforcement officers made nearly 5,000 cannabis-related arrests in 2020, a year wracked by the social and economic fallout of the Covid-19 pandemic. According to the data published in the DEA’s yearly Domestic Cannabis Eradication/Suppression Program Statistical Report, approximately 4.54
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA. More CBD Coverage.
Well, the DEA just released its 2020 National Drug Threat Assessment, and the report is full of stats on the United States’ most popular illegal addictions, new trends in intoxicants, and foreign trade — a.k.a. The US sourced 92 percent of its heroin from Mexico in 2019, according to product analyzed by a DEA tracing program.
As of the time of this writing, the bill’s text is not available on Congress.gov but is provided by Marijuana Moment’s Kyle Jaeger, who wrote a great article on the bill. other known or potential challenges by the participation of States or producers in the domestic hemp production program.
Hawaii House Approves Proposal For Cannabis Exemption From DEA. Hawaii lawmakers approved Wednesday a proposal that seeks an exemption from Drug Enforcement Administration (DEA) regulations, asking that the state is allowed to manage its medical cannabis program without federal involvement, reported Marijuana Moment.
Note: South Dakota’s weed-legalization legislation is currently facing legal challenges, because no list in this article can be simple. Mississippians have also voted to establish a medical marijuana program, but that legislation is still pending.). South Dakota*. Washington. Washington D.C. New Hampshire. North Dakota. Pennsylvania.
Indeed, the DEA reports that it is “aggressively striving to halt the spread of cannabis cultivation in the United States,” including through its Domestic Cannabis Eradication/Suppression Program (DCE/SP), which began funding eradication programs in 1979 and has approximately 126 state and local law enforcement agency participants.
Indeed, the DEA reports that it is “aggressively striving to halt the spread of cannabis cultivation in the United States,” including through its Domestic Cannabis Eradication/Suppression Program (DCE/SP), which began funding eradication programs in 1979 and has approximately 126 state and local law enforcement agency participants.
Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear.
Cannabinoid Hemp Program Regulations (Finally) Finalized. While much attention is focused on New York’s adult-use cannabis market, the CCB and Office of Cannabis Management (OCM) are also responsible for overseeing both the Medical Marijuana and Cannabinoid Hemp Programs.
Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Back in 2018, the DEA rescheduled GW Pharmaceuticals ‘ (NASDAQ: GWPH) cannabis-based epilepsy medicine, Epidiolex, following its regulatory approval by the FDA. Fortunately, this issue shouldn’t be a show-stopper.
The DEA, which enforces the CSA, has indicated that it may consider delta-8 derived from hemp to be a “synthetically derived tetrahydrocannabinol” which still belongs on Schedule I of the CSA. Cultivation, transportation, and sale of unprocessed hemp in New York is governed by Article 29 of the Agriculture & Markets law.
At the time of this article’s publishing, thirty states and the District of Columbia have enacted legislation permitting use of medical cannabis. There is no universal handbook for a medical cannabis program. The best way to become familiar with your state’s medical marijuana program is to visit its official website.
During the keynote session titled “Sue’n the DEA: The Story of a Cannabis Research Breakthrough,” Dr. Sisley—a pioneering medical cannabis researcher and volunteer medical director for more than 40 state cannabis licenses—will share her journey on navigating scientific and legal complexities of medical cannabis research.
This was part of their “Hemp for Victory Program.” However, in 2004, there was a lawsuit against the Hemp Industries Association and the DEA. Then in 2014, Obama signed the Farm Bill, which would then allow pilot programs for growing hemp, but it still wasn’t supposed to be used commercially. Conditions.
In October, Senator Mitch McConnell directed the DEA to figure out how to distinguish hemp from marijuana. As this article notes, sometimes it’s hard to get everyone on the same page, even if they belong to the same political party. The crisp autumn winds of September brought with them the SAFE Act’s passage in the House.
Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. Epidiolex, an FDA-approved medication containing CBD, has been listed as Schedule 5 classification by the DEA since June 25th, 2019. Cannabis is a schedule 1 substance.
From the Fair Labor Standards Act to the STATES Act , our articles run the gamut. Not long ago we wrote about a decision by the Second Circuit that may force the DEA to re- or deschedule marijuana after writing about the lawsuit when it was first filed last year. We’ve written a lot about cannabis and the Controlled Substances Act.
The Drug Enforcement Administration [DEA] later followed that move with its own approval of Epidiolex, as well.). ” ]]> View original article. In 2018, the FDA approved GW Pharmaceuticals’ epilepsy drug, Epidiolex, which contained CBD as an active ingredient.
Later that year, Doblin sued the DEA for the first time. MAPS continued to publish Bulletin articles about MDMA research , requests for donations , and discontinuing animal studies. submitted his first DEA application to manufacture marijuana for use in medical research. MAPS Founder Rick Doblin, Ph.D., Lyle Craker, Ph.D.,
However, when a bill that restricted the medical program was introduced just a few days later, Governor Polis allegedly stopped communicating with the family and other advocates about their wants and needs. . View original article. Polis didn’t have a conversation with us.
This article provides an overview of the current state of legality of common psychedelic substances, and some of the potential therapeutic uses to which psychedelics may be applied. Drug Enforcement Agency (“DEA”). The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.”
The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. This trial will be the second of its kind to be conducted so far, and one that is an FDA- and DEA-regulated double-blind, placebo-controlled study. View original article.
It also includes comprehensive restorative justice provisions, including grants, loans, and other funding programs for disadvantaged and minority businesses, record expungement, petitions for resentencing, and other measures intended to repair the decades of harm caused by the War on Drugs.
1, Louisiana’s medical cannabis program allows patients to access smokable whole-plant flower marijuana. 1, out-of-state medical marijuana patients may access Arkansas’ program to purchase cannabis for up to 90 days. 16 In the Weeds article) from the U.S. Louisiana: As of Jan. Arkansas: As of Jan.
Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. View original article. By Paul Armentano. One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition.
Accordingly, state pesticide programs have tried to provide some clarity to fill the gap left by EPA. pursuant to Drug Enforcement Agency (DEA) or state-level programs). The views and opinions expressed in the article represent the view of the authors and not necessarily the official view of Clark Hill PLC.
Fried remembers the debate, featuring a then- High Times editor and a DEA agent, marking the first substantive cannabis conversation during her time at school. . Since 2014, the state has made incremental progress, first legalizing CBD oil, then expanding its medical program in 2016. View original article.
The informed patients, cannabis industry employees, and clinicians find it equally difficult to keep updated on Florida’s latest medical marijuana program news and changes. . Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S. Federal Register. .
Department of Agriculture (USDA), not the Drug Enforcement Agency (DEA). Until the regulatory framework of the 2018 Farm Bill is fully implemented, hemp will remain governed under the existing 2014 Farm Bill and the rules of its corresponding state pilot programs. The 2018 Farm Bill means that hemp will be regulated by the U.S.
A timeline of Florida’s battle for solid ground has been outlined in depth throughout my previous articles. ” What specific growth did the current Florida program experience? How did the setbacks of our current state program play out nationally in July 2019 ? What are the associated implications? OTCQX: TCNFF.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). Lack of write-ups could suggest to investigators that there is no compliance program at all, thereby making the company’s license suspension or revocation more likely.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). Lack of write-ups could suggest to investigators that there is no compliance program at all, thereby making the company’s license suspension or revocation more likely.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). Lack of write-ups could suggest to investigators that there is no compliance program at all, thereby making the company’s license suspension or revocation more likely.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). Lack of write-ups could suggest to investigators that there is no compliance program at all, thereby making the company’s license suspension or revocation more likely.
Most countries with any type of marijuana program now acknowledge both medical and scientific marijuana. As I discussed in The Hidden Potential Winners of Marijuana Rescheduling: DEA-Registered Bulk Manufacturers , U.S. As I discussed in The Hidden Potential Winners of Marijuana Rescheduling: DEA-Registered Bulk Manufacturers , U.S.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). Lack of write-ups could suggest to investigators that there is no compliance program at all, thereby making the company’s license suspension or revocation more likely.
The Drug Enforcement Administration (DEA) published its Notice of Proposed Rulemaking (“NOPR”) last week to much fanfare. In my very quick analysis after the rule dropped, I flagged DEA’s statement that it may develop “marijuana-specific controls” in conjunction with rescheduling. Marijuana-specific controls in schedule III?
Here is a good article by Hemp Grower magazine on the reopening). Nathalie Bougenies recently wrote about a lawsuit filed against the DEA by the Hemp-CBD industry and we have written several times about the problems with the DEA’s rule: Watch Out! The DEA Does Not Want You To Worry About Its New Hemp Rule.
So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” Last July, researchers published a study of the use of DMT to treat U.S.
My latest selection of links to articles and updates around the country in August. Virginia 2024 adult use program may be postponed: [link]. DEA grants research license for psychedelics and major depression first human trial: [link]. Cannabinoids. Delta 8 now legal in Kentucky: [link].
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content